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Purpose. Rats with experimental Parkinson’s disease (PD) are treated with intravenous glial-derived
neurotrophic factor (GDNF) plasmid DNA and non-viral gene therapy using Trojan horse liposomes
(THLs) targeted with a monoclonal antibody (MAb) to the rat transferrin receptor (TfR). The GDNF
transgene expression is under the inﬂuence of the rat tyrosine hydroxylase (TH) promoter.
Methods. The GDNF expression plasmid is designated pTHproGDNF. Rats were treated with 3 weekly
injections of THLs starting 1 week after the intra-cerebral injection of 6-hydroxydopamine. The dose of
the pTHproGDNF was 10 μg/rat/weekly injection. Rats were tested with three assays of neurobehavior,
and terminal striatal TH enzyme activity was measured at 6 weeks following toxin administration, which
is 3 weeks following the last administration of THLs.
Results. Apomorphine-induced contralateral rotation was reduced 87% by THL gene therapy;
amphetamine-induced ipsilateral rotation was reduced 90% by THL gene therapy; whisker-induced
forelimb placement abnormalities were reduced 77% with THL gene therapy. The improvement in
neurobehavior correlated with a lasting 77% increase in striatal TH enzyme activity, relative to saline
treated rats.
Conclusions. Near complete abrogation of the neurotoxin effects are achieved with multiple intravenous
dosing of GDNF plasmid DNA gene therapy, using receptor-targeted THLs, and a region-speciﬁc
promoter.
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INTRODUCTION
Glial-derived neurotrophic factor (GDNF) is a potent
neurotrophic factor for the catecholaminergic system (1–3),
and GDNF protein therapy is a potential treatment of
Parkinson’s disease (PD). However, GDNF does not cross
the blood–brain barrier (BBB) (4,5). The intra-cerebral
injection of either adeno-associated virus (AAV) or retroviral
vectors expressing GDNF rescues neurons of the nigra-
striatal tract in experimental PD (6–10). Since viral vectors
do not cross the BBB, viral GDNF gene therapy of PD
requires a trans-cranial injection of the virus. Since PD affects
a very large number of individuals, it is desirable to develop
non-invasive, non-viral GDNF gene delivery systems, which
are administered by intravenous injection.
In a previous study, a modest rescue of the nigra-striatal
tract in experimental PD was obtained with a single
intravenous administration of a GDNF expression plasmid
without viral vectors (11). The GDNF transgene was placed
under the inﬂuence of the 8 kb rat tyrosine hydroxylase (TH)
promoter, so as to restrict GDNF expression to catechol-
aminergic cells in brain, thereby reducing off-target effects of
the therapy. The GDNF expression plasmid DNA, designated
pTHpro-GDNF, was delivered to brain with Trojan horse
liposomes (THLs), also called pegylated immunoliposomes
(12). The plasmid DNA is encapsulated in the interior of
100 nm liposomes, and the surface of the liposome is
conjugated with several thousand strands of polyethylenegly-
col (PEG). The tips of 1–2% of the PEG strands are
conjugated with a receptor-speciﬁc monoclonal antibody
(MAb), such as an MAb to the transferrin receptor (TfR).
The TfR is expressed on both the BBB and on the neural cell
membrane. The MAb portion of the THL binds the BBB
receptor, and this triggers receptor-mediated transport across
the BBB, followed by receptor-mediated endocytosis into
neurons behind the BBB (13–16). The purpose of the present
study was to examine if a greater therapeutic effect could be
obtained with a longer course of THL gene therapy.
MATERIALS AND METHODS
Materials. Palmitoyl-2-oleoyl-sn-glycerol-3-phosphocho-
line (POPC), dimethyldioctadecyl ammonium bromide
(DDAB), distearoyl phosphatidylethanolamine (DSPE)-
PEG2000, and DSPE-PEG2000-maleimide were purchased
from Avanti-Polar Lipids (Alabaster, AL), where PEG2000 is
2000 Da polyethylene glycol. The hand-held LipoFast-Basic
extruders, 400-, 200- and 100-nm pore size polycarbonate
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membranes were purchased from Avestin Inc. (Ottawa,
Canada). The genetic engineering, DNA sequencing, and
restriction endonuclease digestion analysis of the pTHpro
GDNF expression plasmid were reported previously (11).
This plasmid encodes for the human prepro GDNF cDNA
(GenBank P39905) corresponding to amino acids Met1-Ile211.
The human prepro GDNF cDNA was subcloned into the
pcDNA3.1 eukaryotic expression plasmid, and the GDNF
cDNA is 3’-ﬂanked by the bovine growth hormone (BGH)
polyA (pA) sequence. The original cytomegalovirus (CMV)
promoter was replaced by the 8 kb of the 5′-ﬂanking
sequence (FS) of the rat TH gene (11). The cloning of the
rat TH promoter has been described previously (17). The
GDNF cDNA is immediately preceded by the full Kozak
sequence (GCCGCCACC).
Trojan Horse Liposomes. Plasmid DNA was prepared
with the Endofree Plasmid Maxi Kit (Qiagen, Valencia, CA).
Supercoiled DNA was 32P labeled with [α-32P]dCTP by nick
translation as described previously (12,18). The
pTHproGDNF plasmid DNA was encapsulated in THLs as
described previously (12,18). The liposome was 100–120 nm
in diameter and the surface of the liposome was conjugated
with several thousand strands of PEG2000. The tips of
approximately 1–2% of the PEG strands were conjugated
with the mouse OX26 MAb to the rat TfR. The OX26 MAb
was puriﬁed by protein G afﬁnity chromatography from
ascites. Any plasmid DNA not encapsulated in the interior
of the liposome was quantitatively removed by nuclease
treatment (12,18). In a typical synthesis, 500 μg of plasmid
DNA was encapsulated within 20 μmol of lipid. The THLs
contained a range of 49–77 MAb molecules per liposome, and
the efﬁciency of the conjugation of the MAb to the maleimide
moiety of the PEG strands ranged from 75–95%. The %
DNA encapsulation was 29±2% for the 13 kb pTHpro-
GDNF DNA. The average diameters of the THLs was
measured with a Nicomp model 380 Particle Analyzer
(Nicomp, Santa Barbara, CA), and was 115±32 nm
following conjugation of the MAb to the liposome.
Tyrosine Hydroxylase Enzyme Activity. TH enzyme
activity in rat brain was measured with [3,5-3H]-L-tyrosine
as substrate; the labeled [3H]-water and [3H]-L-DOPA were
assayed with a charcoal separation technique, and data
reported as pmol per hour per mg protein, as described
previously (19).
6-hydroxydopamine Model of Experimental Parkinson’s
Disease. All procedures were approved by the UCLA
Animal Research Committee. Adult male Sprague-Dawley
rats (supplied by Harlan Breeders, Indianapolis, IN) weighing
220–240 g were anesthetized with ketamine (50 mg/kg) and
xylazine (4 mg/kg) intraperitoneally. Animals received a
unilateral intra-cerebral injection of 8 μg of 6-hydroxydop-
amine into the right medial forebrain bundle, as described
previously (19). Rats were treated with either saline, or THLs
containing 10 μg/rat of pTHproGDNF plasmid DNA at 1, 2,
and 3 weeks after toxin injection. Beginning 1 week after the
toxin administration, rats were tested weekly for apomor-
phine- and amphetamine-induced rotation. For the apmor-
phine testing, rats were administered apomorphine (0.5 mg/
kg) injected intraperitoneally. Full (360°), contralateral rota-
tions only were counted over 20 min, starting 5 min after
apomorphine administration. For the amphetamine testing,
rats were administered amphetamine (5.0 mg/kg) injected
intraperitoneally. Full (360°), ipsilateral rotations only were
counted over 20 min, starting 5 min after amphetamine
administration. Rats were individually identiﬁed so that the
rotations per minute (RPM) before and after gene therapy
could be compared for each rat.
Vibrissae-Elicited Forelimb Placing Test. Each vibrissae-
elicited forelimb placing trial was carried out as described by
Anstrom et al. (20), and demonstrated by video (http://
homepage.psy.utexas.edu/HomePage/Group/SchallertLAB/
media.html). Each session included 120 trials (60 left side and
60 right side) in which a forelimb motor response to
ipsilateral facial whisker stimulation was scored. In trials
scored as a “3”, paw pads made full contact with table top. In
trials scored as a “2”, paw pads do not make contact with the
table. In trials scored as a “1” the limb moves forward only. In
trials scored as a “0”, the limb does not move. A maximal
possible score is 180, wherein the paw pad makes full contact
with the table top in all 60 trials.
Statistical Analyses. Statistically signiﬁcant differences
were assessed with either paired Student’s t-test or analysis
of variance (ANOVA) using the Tukey post-hoc correction.
A p value<0.05 was considered signiﬁcant.
RESULTS
The evolution of the 6-hydroxydopamine lesion was
monitored by neurobehavior assays using apomorphine-
induced and amphetamine-induced rotation, as described in
Fig. 1. In the saline treated animals, the drug induced rotation
increased linearly for 6 weeks following the single intra-
cerebral injection of toxin, for both apmorphine (Fig. 1A) and
amphetamine (Fig. 1B). The THL-treated animals were
administered 10 μg DNA/rat of the pTHproGDNF plasmid
at 1, 2, and 3 weeks after toxin administration, as noted by the
arrows in Fig. 1A. Following apmorphine administration, the
contralateral rotation increased to 24.5±2.4 RPM (mean±SE,
n=10 rats/group) by 6 weeks after toxin administration in the
saline treated animals. However, in the THL treated animals,
the apomorphine-induced rotation was not increased with
time, and the animal rotation, 3.3±0.8 rpm, was decreased
87% (Fig. 1A). Following amphetamine administration, the
ipsilateral rotation increased to 10.7±0.7 RPM (mean±SE, n=
10 rats/group) by 6 weeks after toxin administration in the
saline treated animals. However, in the THL treated animals,
the amphetamine-induced rotation was not increased with
time, and the animal rotation, 1.1±0.2 RPM, was decreased
90% (Fig. 1B).
The apmorphine-induced rotation observed in this study,
which administered the THLs at 1, 2, and 3 weeks after the
toxin (Fig. 1A), was expressed as a ratio of the RPM in the
THL treated animals divided by the RPM in the saline
treated rats at 3–6 weeks after toxin injection (Fig. 2). The
same ratio was computed from the prior study (11), where the
PD rats were treated with only a single injection of THLs at
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2 weeks after toxin administration, and these data are also
plotted in Fig. 2. The comparison shows the marked improve-
ment in neurological function with the repeat THL dosing.
An alternative measure of neurobehavior, the vibrissae-
elicited forelimb placing test, was used to test the pharmaco-
logic efﬁcacy of the THL gene therapy. The unilateral
6-hydroxydopamine lesioned rat fails to place the forelimb
contralateral to the lesion. The forelimb placement score was
nearly perfect, 176±1 (mean±SE, n=10 rats/group), for the
right forelimb, which is ipsilateral to the lesion, in either
the saline treated or THL treated rats (Fig. 3). However,
the forelimb placement score was reduced 77% on the left side
in the saline treated animals to 41±4 (Fig. 3). In contrast, the
forelimb placement score was reduced only 18% in the THL
treated rats, from 178±1 to 146±7 (Fig. 3).
The striatal TH enzyme activity was measured at 6 weeks
after toxin administration for both the lesioned and non-
lesioned sides of brain in the saline and THL treated rats, and
these data are shown in Fig. 4. There was a 99% reduction in
striatal TH enzyme activity on the lesioned side in the saline
treated animals (Fig. 4). However, the reduction in striatal
TH enzyme activity was only 23% in the animals treated with
THLs at 1, 2, and 3 weeks after toxin injection (Fig. 4). In
contrast, the striatal TH was reduced 91% in the rats treated
with a single injection of THLs at 2 weeks after toxin
administration (Fig. 4).
DISCUSSION
The results of this study provide evidence for a near
complete rescue of the toxic effects of intra-cerebral 6-
hydroxydopmine in experimental PD treated with GDNF gene
therapy given intravenously and without viral vectors. The
experimental design includes three different assays of neuro-
behavior (Figs. 1, 2, and 3), and measurements of striatal TH
enzyme activity (Fig. 4). In comparison to the results of a
previous study (11), the present investigation shows the greater
therapeutic effect of GDNF gene therapy when THLs are
given at repeat dosing early after toxin exposure.
Fig. 2. The ratio of apomorphine-induced rotation in the THL
treated rats divided by the apomorphine-induced rotation in the
saline treated rats was derived from the data in Fig. 1 for the animals
treated at 3–6 weeks, and from Xia et al. (11) for the rats treated with
a single dose at 2 weeks after toxin administration. Data are mean±
SE (n=10 rats/group).
Fig. 3. Vibrissae-elicited forelimb placing test scores for right side,
which is ipsilateral to the toxin lesion, and the left side, which is
contralateral to the toxin lesion, for the saline treated rats and the
THL treated rats. All scores were measured at 6 weeks following
toxin injection, which is 3 weeks after the last THL administration.
Data are mean±SE (n=10 rats/group).
Fig. 1. Rotation measurements following the administration of either apomorphine (A) or amphetamine
(B) for PD rats treated with either saline or THLs. Treatment was administered at 1, 2, and 3 weeks after
toxin injection as indicated by the arrows in A. RPM rotations per minute. Data are mean±SE (n=10 rats/
group). Statistical differences from the saline treated animals are *p<0.05, ‡p<0.005, or †p<0.0005 at 3, 4,
5, or 6 weeks after toxin administration.
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In the present study, the control animals were treated
with saline. Prior work showed there is no therapeutic effect
in the experimental PD model when the rats are treated with
a THL formulation that is identical to the TfRMAb-targeted
THLs, except the TfRMAb is replaced by an IgG2a isotype
control antibody (19). Previous organ biodistribution studies
show the brain targeting of the pegylated liposome is
increased >10-fold following conjugation of the TfRMAb to
the tips of the PEG strands on the surface of the THL (21).
Previous histological studies demonstrated THL gene thera-
py, with a TH expressing plasmid DNA, causes an increase in
TH enzyme activity throughout the striatum (19), and THL
gene therapy, with a GDNF expressing plasmid DNA, causes
an increase in GDNF in the substantia nigra (11). There are
no side effects of repeat intravenous THL administration. A
prior toxicity study showed no changes in serum chemistry or
histology in brain or peripheral organs following the chronic
weekly administration of THLs (22).
There are several aspects of the THL formulation, which
enabled the successful therapeutic outcome. First, neuro-
trophin gene therapy, and in particular GDNF gene therapy,
is known to rescue the nigra-striatal system in experimental
PD when the GDNF gene is injected directly into the brain
(6–10). The present study extends these ﬁndings to the
experimental setting where the GDNF transgene is adminis-
tered intravenously without viral vectors. This is enabled by
encapsulating the GDNF plasmid DNA in 100 nm pegylated
liposomes, which are targeted with a molecular Trojan horse
—an MAb against the rat TfR. The TfR is highly expressed
on the BBB (23), and enables the receptor-mediated trans-
cytosis (RMT) across the BBB of either the endogenous
ligand, transferrin, or a peptidomimetic TfRMAb (24). The
incorporation of the TfRMAb in the THL formulation
enables the plasmid DNA, encapsulated in the THL, to
undergo RMT across the BBB (12–16). In addition, the TfR is
highly expressed on neurons (25). Binding of the TfRMAb to
the neuronal TfR enables the THL to undergo receptor-
mediated endocytosis into neurons. This has been demon-
strated previously for rodent and primate brain using a
beta-galactosidase reporter plasmid DNA (12–16). Finally,
the GDNF expression plasmid, pTHproGDNF, was engi-
neered to place the preproGDNF transgene under the
inﬂuence of the 8 kb of the 5’-FS of the rat TH gene (11).
This restricts transgene expression in brain to the catechol-
aminergic system (26–29), which reduces potential off-target
effects of the gene therapy.
The restricted nature of GDNF gene expression from the
pTHproGDNF plasmid DNAwas demonstrated in a previous
study (11). Following the intravenous injection of THLs
carrying the pTHproGDNF, GDNF expression was measured
in a survey of peripheral rat tissues, and in multiple regions of
the brain. The GDNF was expressed in brain only in the
substantia nigra, and was only expressed in peripheral tissues,
such as liver or adrenal gland, where the TH promoter is
active. The highly restricted nature of GDNF gene expression
under the inﬂuence of the TH promoter, as compared to the
CMV promoter, was demonstrated previously in COS cells
(11). The level of GDNF gene expression in COS cells was
two to three log orders of magnitude reduced when the CMV
promoter was replaced by the TH promoter (11).
The GDNF expression in the rat in vivo peaks at 6 days,
and persists for at least 10 days, after a single THL
administration (11). Therefore, in the present study, the
THLs were administered weekly for three successive weeks,
beginning at 1 week after toxin administration (Fig. 1A).
With this treatment schedule, the nigral-striatal tract is
believed to be exposed to sustained elevations in GDNF for
approximately 4 weeks. This is corroborated by the observa-
tion of the much greater therapeutic effect with multiple THL
dosing as opposed to single THL dosing (Fig. 2). The tissue
concentration of GDNF is increased 2- to 8-fold in those
organs that express the TH promoter (11). Thus, relatively
modest increases in brain GDNF provide a marked degree of
neuroprotection. This observation is consistent with studies
producing an approximate 3-fold increase in the local
concentration of GDNF with a trans-cranial injection of a
GDNF expressing viral vector (8). This modest increase in
GDNF was highly neuroprotective in the nigral-striatal tract,
but did not cause off-target effects or GDNF-induced
neuronal sprouting (8).
In summary, the present study shows that a near
complete recovery from a nigral neurotoxin is possible with
intravenous, non-viral GDNF gene therapy given for 3 weeks
early in the course of the evolution of the toxin-induced
lesion. The plasmid DNA expressing the GDNF was delivered
to all parts of the brain via the trans-vascular route across the
BBB with Trojan horse liposomes. However, since the
expression of the GDNF transgene was under the inﬂuence
of the TH promoter, GDNF expression in the brain is conﬁned
to the narrow regions of brain that express the TH gene.
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Fig. 4. Striatal TH enzyme activity on the lesioned side and the non-
lesioned side in rats treated with either saline or THLs. THL
treatment was administered at either 1, 2, and 3 weeks after toxin
injection (this study) or as a single dose at 2 weeks after toxin
injection (11). Striatal TH activity was measured at 6 weeks after
toxin administration. Data are mean±SE (n=10 rats/group).
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